ALISO VIEJO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Michele Hibbard, Ph.D., a veteran clinical molecular biologist and cytogeneticist, has been named to the newly created position of Director of Genetics, effective immediately. She reports directly to Ken Bloom, M.D., FCAP, Chief Medical Officer and Medical Director.
Hibbard, 41, a resident of Irvine, CA, joins Clarient after spending six years as Director of Genetics at Irvine-based U.S. Labs, where she helped launch and direct the operations of the genetics program. She was responsible for the technical operations, including policy review, new procedure validation and case review/sign out, of the cytogenetic, FISH and molecular genetic laboratories.
"Michele's expertise in laboratory science, systems and quality operations complements our management team and enhances the needs of the laboratory, which have evolved over the past three years as our laboratory operations have grown," said Clarient President and CEO Ron Andrews. "Having an experienced individual like Michele to manage Clarient's expanding molecular lab services is essential to continue our growth velocity. Michele has an excellent track record, which includes starting up new labs to overseeing a laboratory's entire operations and is an excellent addition to an outstanding leadership team. As molecular genetics assumes a leading role in the theranosis of cancer, Michele's experience will be a perfect fit for us as we build out our novel marker capabilities in this exciting area. We look forward to the value that she will bring to Clarient and those we serve."
Prior to her work at U.S. Labs, Hibbard spent a year as Director of Cytogenetics at IMPATH, Inc, where she started up their New York cytogenetic operation. She completed her postdoctoral research in the Department of Pathology at Brigham and Women's Hospital in Boston and her thesis research in the Department of Microbiology and Molecular Genetics at UC Irvine. Hibbard began her career in genetics as a cytogenetic technologist, working at San Juan Capistrano, CA-based Nichols Institute.
Hibbard has a bachelor's degree in biology from UC San Diego and a Ph.D. in biological sciences from UC Irvine. She earned a certificate from the American Board of Medical Genetics in Clinical Molecular Genetics and Clinical Cytogenetics after training at Harvard Medical School. She is also a licensed Clinical Genetic Molecular Biologist and Clinical Cytogeneticist by the State of California Department of Health Services.
Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. For more information, visit http://www.clarientinc.com.
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company, builds value in growth-stage technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. Safeguard participates in growth buyout financings, including corporate spin-outs and management buyouts, expansion financings, industry consolidations and early-stage financings. http://www.safeguard.com
The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company's ability to successfully implement the management changes described above, the Company's ability to continue to develop and expand its diagnostic services business, the Company's ability to expand and maintain a successful sales and marketing organization, the Company's ability to maintain compliance with financial and other covenants under its credit facilities, the continuation of favorable third party payer reimbursement for laboratory tests, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.
The company does not assume any obligation to update any forward-looking statements or other information contained in this document.
Matt Clawson John Baldissera
Allen & Caron, Inc. BPC Financial Marketing
(949) 474-4300 (800) 368-1217
|SOURCE Clarient, Inc.|
Copyright©2007 PR Newswire.
All rights reserved